One of the applications that UltraVision is being prepared for is the Breast Cancer Market. Components for this market are in the following status:
B-Mode for solid vs cyst determinations product has FDA 510k and may be sold today.
Fine needle Biopsy Guidance is just a software algorithm and is available today.
Color Flow Doppler for evaluation of vascularity product has FDA 510k and may be sold today.
Compression Elastography for evaluation of relative tissue hardness is approved and may be sold today.
Shear Elastography for the quantitative estimation of tissue hardness is developed.
Visualization of microcalcifications is an algorithm that does not affect the power output and is available today.
An Automatic Breast Screening System attachment to the UltraVision is in the concept phase and is expected to be available to the market within 2 years.
We are seeking partners to assist in the development of breast market products.